YMB


“Anyone else putting the correlation between the 8k which was a deal completed on January 13th to today's announcement?

Anyone tie in the interim COB being the newest board member with SEC legal experience?

Anyone notice Dr. Kelly's statement "to benefit patients, partners and shareholders", not "patients, shareholders and potential partners"?

Connect the dots.

Wouldn't a new partner want seats on the board? Especially CEO and COB?

Wouldn't a new partner want someone with SEC legal experience at the helm to ensure smooth transition and avoid any legal obstacles?

So, if a partnership or buyout, who?

Logic dictates Sidley or Samsung. Both would be willing to enter the pharmaceutical sector. Sidley is already entrenched. Samsung is looking to expand.

Big pharma is utilizing "pay to delay" tactics in the belief that they can catch up or be granted approval even with a black box warning.

My question, who are the three investors who bought stock on January 13th?

New partners or Golden parachute?”